Search
Fontolizumab
go.drugbank.com/drugs/DB05111InvestigationalFontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.
Oleoyl-estrone
go.drugbank.com/drugs/DB04870InvestigationalIt has been shown in animal studies to promote the loss of body fat while maintaining body protein storage, maintaining nitrogen balance. … Oleoyl-estrone (OE) is a fatty acid ester of estrone. This hormone occurs naturally and is found circulating in various animal species and humans.
INKP-102
go.drugbank.com/drugs/DB05326ExperimentalINKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.
ALS-08
go.drugbank.com/drugs/DB05705ExperimentalALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
INZ-701
go.drugbank.com/drugs/DB17629InvestigationalINZ-701 is an enzyme replacement therapy under development with the intention to be used for the treatment of calcification disorders of the circulatory system, bones, and kidneys.
Synonyms: Recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IGG1 (INZ-701)IP501
go.drugbank.com/drugs/DB06450ExperimentalIP-501 is an investigational antifibrotic compound being tested for the treatment of alcohol-induced liver disease and chronic hepatitis-C-induced cirrhosis.
Methamidophos
go.drugbank.com/drugs/DB14972ExperimentalLeukemia in First Remission). … Methamidophos is under investigation in clinical trial NCT03223753 (Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic
Categories: Compounds used in a research, industrial, or household settingAZD7442
go.drugbank.com/drugs/DB15787InvestigationalAZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. … [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]
Categories: Experimental Unapproved Treatments for COVID-19Arginine glutamate
go.drugbank.com/drugs/DB13207InvestigationalMixtures: NUTRIFLEX PLUS IN 1000ML TWIN FLEX, NUTRIFLEX PLUS IN 2000ML TWIN FLEXDanoprevir
go.drugbank.com/drugs/DB11779InvestigationalDanoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.